Novo Nordisk: Oral Wegovy Approval Buoys Stock, but Pipeline Data Highlights Lilly’s Lead
12.06.2026 - 03:52:56 | boerse-global.de
The UK’s drugs regulator has handed Novo Nordisk a strategic win for its oral version of Wegovy, giving the Danish drugmaker fresh ammunition in its battle to expand the weight-loss market. The MHRA decision sent shares up 2.4 percent to €37.98 on the day of the announcement, a modest gain that hints at a market weighing positive catalysts against persistent competitive headwinds.
Britain becomes the third major jurisdiction to approve once-daily semaglutide tablets for weight reduction, following the US and the United Arab Emirates. The regulatory nod rests on the OASIS-4 trial, where patients lost 16.6 percent of their body weight over 64 weeks — a clear gap over placebo. More tellingly, the oral formulation is already reshaping patient behaviour in the US. Since its early 2026 launch, more than three million prescriptions have been filled, and over 80 percent of those patients had never taken a GLP-1 drug before. That is not cannibalisation; it is market expansion, and it lowers the psychological barrier to entry that injections create.
Yet the stock remains deep in the red over the longer term. At roughly €38, the shares trade 46 percent below last June’s 52-week high of €70.13. The light at the end of the tunnel for technical traders is that the price now sits about 5 percent above its 50-day moving average of €36.25, while the relative strength index reads 53 — a neutral zone far removed from the oversold territory seen earlier in the year.
The pipeline news flow has done little to shift the narrative, largely because the competition keeps raising the bar. At this year’s premier diabetes conference, Novo Nordisk presented Phase 2 data for zenagamtide — the drug formerly known as Amycretin. In a dose-finding study of 262 patients with type 2 diabetes, the highest subcutaneous dose delivered an average weight loss of 14.6 percent after 36 weeks and cut HbA1c by up to 1.71 percentage points. Nearly 89 percent of that group reached the clinically meaningful target of less than 7 percent. Zenagamtide is a dual GLP-1 and amylin receptor agonist, a combination that sets it apart from standard GLP-1s. Novo plans to launch Phase 3 for type 2 diabetes in the second half of 2026.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Meanwhile, the company also unveiled the full Phase 3 results from the REIMAGINE programme for CagriSema, a fixed-dose combination of a novel amylin analogue and semaglutide. All three studies hit their primary endpoints on HbA1c reduction and confirmed secondary weight-loss goals. Results appeared simultaneously in The Lancet Diabetes & Endocrinology and The Lancet. An FDA application for a weight-loss indication is already in, and a US launch is pencilled in for early 2027.
The problem is comparative performance. In the head-to-head REDEFINE-4 trial, CagriSema produced a 23 percent weight reduction over 84 weeks. Lilly’s Zepbound managed 25.5 percent, and retatrutide — Lilly’s next-generation triple agonist — hit 28 percent at the same conference. That efficacy gap explains why the market has largely shrugged off Novo’s otherwise solid data.
Separately, the company disclosed a cyberattack on June 11, 2026. Unauthorised third parties accessed internal systems and copied pseudonymised patient data from clinical trials, including IDs, birth years and health information. Novo Nordisk took systems offline and brought in external experts. The incident is not trivial — regulatory scrutiny is likely — but production and pipeline work continue normally, and the stock’s positive reaction suggests investors see it as a manageable operational risk rather than a strategic threat.
A broader structural catalyst awaits both Novo and Lilly. From July 1, millions of US seniors with Medicare will be able to access GLP-1 medications for weight loss at a monthly cost of $50, opening a vast new addressable market. That tailwind benefits both rivals equally, but Novo’s ability to capture share will depend heavily on how quickly it can roll out the oral formulation globally.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Chief executive Mike Doustdar, in post since August 2025, is driving a “Weight and Beyond” strategy that aims to broaden the company’s reach beyond injectables. Early US prescription data suggests the approach is working. In the UK, the oral drug is expected to launch via private prescriptions in the coming weeks, with a wider rollout in the second half of 2026.
For a stock that has lost nearly half its value from the peak and suffered multiple profit warnings in the past year, the oral pill represents something more than a product extension. It is a chance to rewrite the narrative — but only if Novo can narrow the efficacy gap that Lilly continues to widen.
Ad
Novo Nordisk Stock: New Analysis - 12 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
